• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Arcus Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

    6/2/25 8:25:32 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCUS alert in real time by email
    rcus-20250601
    false000172452100017245212025-06-012025-06-01

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ________________________________________________________
    FORM 8-K
    ________________________________________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): June 1, 2025
    ________________________________________________________
    Arcus Biosciences, Inc.
    (Exact name of Registrant as Specified in Its Charter)
    ________________________________________________________
    Delaware001-3841947-3898435
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
    3928 Point Eden Way
    Hayward, California
    94545
    (Address of Principal Executive Offices)(Zip Code)
    Registrant’s Telephone Number, Including Area Code: (510) 694-6200
    (Former Name or Former Address, if Changed Since Last Report)
    ________________________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading
    Symbol(s)
    Name of each exchange on which registered
    Common Stock, Par Value $0.0001 Per ShareRCUSThe New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 7.01    Regulation FD Disclosure.
    On June 1, 2025, Arcus Biosciences, Inc. (the “Company”) presented updated information about its portfolio and development programs. An updated corporate presentation has been posted to the Investors & Media section of the Company’s website.
    Item 8.01    Other Events.
    The presentation included updated data from the interim analysis of the Company’s Phase 1/1b study clinical trial ARC-20. The data was from the study's cohort that is evaluating once-daily 100mg of casdatifan plus 60mg of cabozantinib in patients with clear cell renal cell carcinoma who had progressed on prior immunotherapy. The efficacy evaluable population included 24 patients who received any study treatment and reached a minimum of 12 weeks follow-up or discontinued due to progression or adverse event and the safety evaluable population included 42 patients who received any amount of study drug and had at least one month of safety follow-up at the data cutoff date. Specifically, the Company disclosed the following information from the interim analysis, which had a data cutoff date of March 14, 2025 (the "DCO"):
    Efficacy EvaluableCasdatifan 100mg QD + Cabozantinib 60mg QD (n=24)
    Median Follow-Up5.3 months
    Confirmed ORR (cORR) per RECIST v1.1 [95% CI]46% (11)*
    [26,67]
    Best Overall Response:       
       - Complete Response     
       - Partial Response     
       - Stable Disease     
       - Progressive Disease
     

    4% (1)
    42% (10)*
    50% (12)
    4% (1)
    * Inclusive of one patient who had a confirmed partial response confirmation after the DCO.
    In the safety-evaluable population, no unexpected safety risks were identified at the time of DCO, and casdatifan plus cabozantinib had an acceptable safety profile with no meaningful overlapping toxicity for the two drugs.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    ARCUS BIOSCIENCES, INC.
    Date: June 1, 2025By:/s/ Terry Rosen, Ph. D.
    Terry Rosen, Ph.D.
    Chief Executive Officer
    (Principal Executive Officer)

    Get the next $RCUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCUS

    DatePrice TargetRatingAnalyst
    2/26/2025$18.00 → $24.00Neutral → Buy
    H.C. Wainwright
    10/21/2024$20.00Neutral
    H.C. Wainwright
    10/8/2024$29.00Overweight
    Wells Fargo
    11/18/2022$33.00Neutral
    BofA Securities
    10/11/2022$40.00Overweight
    Morgan Stanley
    11/19/2021$42.00 → $53.00Buy
    Citigroup
    11/19/2021$48.00 → $60.00Overweight
    Barclays
    11/18/2021$68.00 → $100.00Outperform
    SVB Leerink
    More analyst ratings